News and Events
Flotsam and Jetsam
NEWS RELEASE
Date: 27 January 2012
Epicore BioNetworks Inc. announces that it has granted stock options to non-executive directors of the company. The number of options granted is 150,000, which is equivalent to 0.6% of Epicore's issued common stock. Under the terms of the Epicore Stock Option Plan, options may be issued from time to time in any amount up to a maximum of 4,704,246 Epicore common shares. These options have an exercise price of Cdn $0.15 and expire in five years. The grant to directors follows Company board compensation policy.
Epicore BioNetworks Inc. is a leading producer of environmental biotechnology and animal nutrition products. It manufactures in the USA and markets worldwide to a variety of industries to reduce environmental pollution and increase operational productivity.
Epicore BioNetworks Inc. is a public corporation with a registered office in Calgary, Alberta, Canada and with shares listed on the TSX Venture Exchange (symbol EBN). [Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.]
For more information, please contact:
Mr. William P. Long (Chief Executive Officer)
USA. Tel: 609-267-9118
Email: Investors@EpicoreBioNetworks.com
NEWS RELEASE
Date: 25 January 2012
Epicore announces that its Chief Executive Officer, William P. Long, and one management employee exercised 366,000 of their allotted common stock options. The options were exercised at the price granted, which was Cdn. $0.10 per share. With this transaction Epicore common shares outstanding increased 1.5% to 24,187,234. Mr. Long's ownership of Epicore shares becomes 300,000, which is 1.2% of shares outstanding.
Epicore BioNetworks Inc. is a leading producer of environmental biotechnology and animal nutrition products. It manufactures in the USA and markets worldwide to a variety of industries to reduce environmental pollution and increase operational productivity. Epicore is a major supplier to the shrimp aquaculture industry.
Epicore BioNetworks Inc. is a public corporation with a registered office in Calgary, Alberta, Canada and with shares listed on the TSX Venture Exchange (symbol EBN). [Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.]
For more information, please contact: Mr. William P. Long (Chief Executive Officer) USA. Tel: 609-267-9118, Email: Information@EpicoreBioNetworks.com
A sales revenue increase of 9% over prior year quarter one (Q1) to $1.11 million set a Company quarter one record. The demand for shrimp remained high throughout the quarter, as it has done for much of calendar 2011. Supply shortages caused by disease and natural disasters have pushed shrimp prices higher. Higher shrimp prices increased the demand for Epicore’s productivity enhancing products. The Epicore sales team and our distributors continued to add new customers and to pursue new applications for Epicore products. Epicore continued a major initiative to increase its science resources, which should position the Company for significant future growth and increase the reliability of its manufacturing operations. Some Q1 highlights were:
- Increased sales 9% versus prior year Q1 to $1.1 million.
- Increased gross profit 1% versus prior year Q1 to $0.6 million.
- Generated another year of positive net income ($0.06 million vs. $0.09 million in prior year Q1).
- Achieved basic and diluted earnings per share of $0.003, down from $0.004 in prior year Q1.
- Increased shareholders’ equity 2% in the quarter to $4.2 million.
- Increased cash to $1.8 million (an 8% increase in the quarter and a 51% over prior year Q1).
- Completed IFRS implementation and took advantage of the extended filing deadline for Q1.
Gross profit grew 1% due to the sales increase. Because of sales mix Epicore gross margin (gross profit as a percentage of sales) decreased. Operational expenses increased by 18% due to inflation, higher marketing travel expense, higher financial expense and one-time expense related to strategic initiatives. Quarter one fiscal 2012 results include a US federal income tax expense of $0.04 million, along with $0.02 million for New Jersey and Ecuadorian taxes. Net income of $0.06 million was lower than fiscal 2011 because of lower gross margin and higher operating expenses, as the following results show (rounded to thousands in US dollars):
2011 2010
Sales 1,114,000 1,024,000
Gross Profit 628,000 621,000
Operating Expenses 509,000 429.000
Earnings Before Tax 126,000 195,000
Income Tax Expense 62,000 104,000
Net Income 64,000 91,000
EBITDA 139,000 204,000
Cash at the end of September was $1.8 million, an increase of 8% over prior year quarter four. With these funds, expected sales revenue growth and continued relatively low operating costs, management expects there will be sufficient cash to meet the fiscal year’s financial requirements, to fund expansion of aquaculture and environmental remediation marketing efforts and to pursue new strategies for enhancing shareholder value. In support of its growth strategy, the Company anticipates additional expenditure during fiscal 2012 in property, plant and equipment, through the addition of leased capital equipment and enhancements to its production facility in New Jersey, and in product development through its ongoing R&D programs. This is expected to be financed by a combination of the Company’s cash reserves, continued positive earnings and third-party financing.
The financial statements of the company have been prepared in accordance with International Financial Reporting Standards. Epicore BioNetworks Inc. is a public corporation with a registered office in Calgary, Alberta, Canada and with shares listed on the TSX Venture Exchange (symbol EBN). [Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.]
This press release contains forward-looking statements that involve significant risks and uncertainties. The actual results, performance or achievements of the company might differ materially from the results, performance or achievements of the company expressed or implied by such forward-looking statements. Such forward-looking statements include, without limitation, those regarding the future growth of the Company, expected improvements in the quality and reliability of manufacturing operations, acceleration of the Company’s penetration into new business areas, the development plans of the company, the expected timing and results of such development and the expectation by management that there will be sufficient cash to meet the fiscal year’s financial requirements. We can provide no assurance that such development will proceed as currently anticipated, that the expected timing or results of such development will be realized or that the company will be able to generate sufficient cash to meet its obligations. We are subject to various risks, including the uncertainties of product development, markets for our products and regulatory review, our need for additional capital to fund our operations, our reliance on collaborative partners, our history of losses, and other risks inherent in the biotechnology industry.
For more information, please contact: Mr. William P. Long (Chief Executive Officer) USA. Tel: 609-267-9118, Email: Investors@EpicoreBioNetworks.com
Epicore fiscal 2011 sales revenue broke the $5 million level for the first time with a 30% increase above prior year. With increased sales and cost control, EBITDA increased 54%.
As the world slowly recovers from a severe economic downturn Epicore has grown strongly and has delivered four quarterly sales records. Demand for shrimp has been high throughout fiscal 2011. Shrimp prices have been high due to supply shortages caused by disease and natural disasters. Producers have relied on Epicore products to deliver higher productivity from their hatcheries and farms. The Epicore sales team and our distributors continued to add new customers and to pursue new applications for Epicore products. While many companies cut back in 2011, Epicore continued a major initiative to improve its science resources, which will position the Company for significant future growth and increase the reliability of its manufacturing operations. Some highlights versus prior fiscal year were:
Increased revenue from $3.8 million to $5.0 million (a 30% increase). Increased gross profit from $2.4 million to $3.0 million (a 23% increase).
Generated another year of positive net income ($0.4 million)
Increased EBITDA from $0.6 million to $0.9 million (a 54% increase).
Achieved basic and diluted earnings per share of $0.02.
Increased shareholders' equity from $3.7 million to $4.1 million (a 12% increase).
Increased cash from $1.0 million to $1.7 million (a 68% increase).
Gross profit grew 23% due to the sales increase. Because of sales mix, Epicore's gross margin did decline. Operational expenses increased by 13% in fiscal 2011 (half the fiscal 2010 increase) due to increased selling effort, inflation and IFRS conversion. Research and development expenses decreased 17% with the expiry of a research consultant contract. With the scientific program in place and the production resources being added, management expects to improve the quality and reliability of its manufacturing operations and to accelerate the Company's penetration into new business areas.
Epicore generated positive net income of $0.4 million to give Epicore its seventh consecutive year of profitable operation. Versus prior year net income decreased by $1.3 million because of the onetime recognition of the future income tax benefit of accumulated USA NOLs that was booked in 2010. One measure that ignores this onetime tax effect is EBITDA, which increased 54% over prior year from $0.6 million to $0.9 million, as the following results (in US$) show:
| (US$) | 2011 | 2010 | |
| Revenue | 5,014,600 | 3,844,100 | Gross Profit | 2,956,300 | 2,396,100 |
| Gross Margin | 59.0 % | 62.3 % | |
| Operating Expenses | 2,072,600 | 1,838,800 | |
| Net Income | 404,300 | 1,335,600 | Basic/diluted net income per weighted avg. common share |
0.02 | 0.06 |
| Shareholder's Equity | 4,109,900 | 3,658,300 | |
| Cash Balance | 1,692,600 | 1,005,300 | |
| Increase in cash | 687,300 | 193,400 |
Epicore continues to generate positive cash flows with an inflow of $0.7 million in fiscal 2011, which was $0.5 million more than fiscal 2010. Cash at the end of the year was $1.7 million. With these funds, expected sales revenue growth and continued relatively low operating costs, management expects there will be sufficient cash to meet the fiscal year's financial requirements, to fund expansion of aquaculture and environmental remediation marketing efforts and to pursue new strategies for enhancing shareholder value. In support of its growth strategy, the Company anticipates additional expenditure during fiscal 2011 in property, plant and equipment, through the addition of capital equipment and enhancements to its production facility in New Jersey, United States of America, and in product development through its ongoing R&D programs. This is expected to be financed by a combination of the Company's cash reserves, continued positive earnings and third-party financing.
The financial statements of the company have been prepared in accordance with Canadian GAAP. Epicore BioNetworks Inc. is a public corporation with a registered office in Calgary, Alberta, Canada and with shares listed on the TSX Venture Exchange (symbol EBN). [Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.]
This press release contains forward-looking statements that involve significant risks and uncertainties. The actual results, performance or achievements of the company might differ materially from the results, performance or achievements of the company expressed or implied by such forward-looking statements. Such forward-looking statements include, without limitation, those regarding the future growth of the Company, expected improvements in the quality and reliability of manufacturing operations, acceleration of the Company's penetration into new business areas, the development plans of the company, the expected timing and results of such development and the expectation by management that there will be sufficient cash to meet the fiscal year's financial requirements. We can provide no assurance that such development will proceed as currently anticipated, that the expected timing or results of such development will be realized or that the company will be able to generate sufficient cash to meet its obligations. We are subject to various risks, including the uncertainties of product development, markets for our products and regulatory review, our need for additional capital to fund our operations, our reliance on collaborative partners, our history of losses, and other risks inherent in the biotechnology industry.
For more information, please contact: Mr. William P. Long (Chief Executive Officer) USA. Tel: 609-267-9118, Email: Investors@EpicoreBioNetworks.com
Epicore announces the appointment of Megasupply of Miami Florida as its distributor for local sales in four Central America countries. For many years, Epicore has been a supplier of aquaculture products in Central America, primarily through indent sales: a viable option for large buyers. With the distributorship Megasupply has been able to open an office in Choluteca, Honduras. With a local stock of Epicore products service to smaller buyers in the region will significantly improve.
Epicore CEO, William Long, Epicore Aquaculture Business Development Director, Fernando Garcia, and Epicore Technical Sales Specialist, Jorge Ullauri, assisted Megasupply President, Jose Curiel, and local Office Administrative Assistant, Sandra Velasquez, open the new office (see picture below). Complimenting the Epicore product line, Megasupply also offers Artemia cysts, aquaculture equipment and other fine products.
Interested customers can visit the office at Oficina #12 Hotel Gualiqueme or call at 504-2782-6230 or email at ventasCA@mega-supply.com. Megasupply can be contacted at 786-221-5660 or be emailed at sales@mega-supply.com. Learn more at www.megasupply.net.
Epicore BioNetworks Inc. is a leading producer of environmental biotechnology and animal nutrition products. It manufactures in the USA and markets worldwide to a variety of industries to reduce environmental pollution and increase operational productivity.
Epicore BioNetworks Inc. is a public corporation with a registered office in Calgary, Alberta, Canada and with shares listed on the TSX Venture Exchange (symbol EBN). [Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.]
This press release contains forward-looking statements that involve significant risks and uncertainties. The actual results, performance or achievements of the company might differ materially from the results, performance or achievements of the company expressed or implied by such forward-looking statements. Such forward-looking statements include, the development plans of the company, and the expected timing and results of such development and the expectation that a local stock of Epicore products will significantly improve service to smaller buyers in Central America. We can provide no assurance that such development will proceed as currently anticipated, that the expected timing or results of such development will be realized or that the company will be able to generate sufficient cash to meet its obligations. We are subject to various risks, including the uncertainties of product development, markets for our products and regulatory review, our need for additional capital to fund our operations, our reliance on collaborative partners, our history of losses, and other risks inherent in the biotechnology industry.
For more information, please contact: Mr. William P. Long (Chief Executive Officer) USA. Tel: 609-267-9118, Email: Investors@EpicoreBioNetworks.com
Epicore announces investment in a major expansion to its Eastampton, NJ facility to support its growing and profitable core aquaculture business and to create new opportunities to enhance shareholder value.
A financing commitment has been secured from a leading North American bank for $1.9 million of production equipment. The new equipment will significantly expand Epicore's current production capacity for biological products. The expansion will improve the reliability and efficiency of current production as well as provide production capability for new products from the Company's research and development program. The expansion is a key element in the Company's diversification program into other areas of environmental biotechnology.
To house the new equipment modifications will be made to the Company's Eastampton site. The modifications include relocating current offices and creating additional production floor space. Local government approvals have been obtained for the building modifications.
Epicore BioNetworks Inc. is a leading producer of environmental biotechnology and animal nutrition products. It manufactures in the USA and markets worldwide to a variety of industries to reduce environmental pollution and increase operational productivity.
Epicore BioNetworks Inc. is a public corporation with a registered office in Calgary, Alberta, Canada and with shares listed on the TSX Venture Exchange (symbol EBN). [Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.]
This press release contains forward-looking statements that involve significant risks and uncertainties. The actual results, performance or achievements of the company might differ materially from the results, performance or achievements of the company expressed or implied by such forward-looking statements. Such forward-looking statements include, without limitation, those regarding the future growth of the Company, expected improvements in the quality and reliability of manufacturing operations, acceleration of the Company's penetration into new business areas, the development plans of the company, the expected timing and results of such development and the expectation by management that there will be sufficient cash to meet the fiscal year's financial requirements. We can provide no assurance that such development will proceed as currently anticipated, that the expected timing or results of such development will be realized or that the company will be able to generate sufficient cash to meet its obligations. We are subject to various risks, including the uncertainties of product development, markets for our products and regulatory review, our need for additional capital to fund our operations, our reliance on collaborative partners, our history of losses, and other risks inherent in the biotechnology industry.
For more information, please contact: Mr. William P. Long (Chief Executive Officer) USA. Tel: 609-267-9118, Email: Investors@EpicoreBioNetworks.com
The Board of Directors of Epicore BioNetworks Inc. is pleased to announce restructuring of the ownership of its Eastampton, NJ site. The limited liability real estate partnership (LLP) that was formed in 2006 to enable Epicore and a non-related neighboring business to acquire their buildings was dissolved effective August 15, 2011 and ownership of the properties was assigned to the two partners. Local government approvals had been obtained for subdivision of the LLP site into three parcels. Each LLP partner acquired the parcel on which their building is located. A third parcel of approximately two acres of unoccupied land adjacent to Epicore but previously owned by the other LLP partner was acquired by Epicore for consideration paid to the other LLP partner. Mortgage financing of the site and extra land was secured from a leading North American bank. The new mortgage carries a significantly lower rate of interest than the 2006 mortgage.
The site restructuring and land acquisition supports Epicore's growing and profitable core aquaculture business and will help create new opportunities to enhance shareholder value. Elimination of the LLP will reduce Epicore administrative costs and eliminate possible liability from association with another unrelated business.
Epicore BioNetworks Inc. is a leading producer of environmental biotechnology and animal nutrition products. It manufactures in the USA and markets worldwide to a variety of industries to reduce environmental pollution and increase operational productivity.
Epicore BioNetworks Inc. is a public corporation with a registered office in Calgary, Alberta, Canada and with shares listed on the TSX Venture Exchange (symbol EBN). [Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.]
This press release contains forward-looking statements that involve significant risks and uncertainties. The actual results, performance or achievements of the company might differ materially from the results, performance or achievements of the company expressed or implied by such forward-looking statements. Such forward-looking statements include, without limitation, those regarding the future growth of the Company, expected improvements in the quality and reliability of manufacturing operations, acceleration of the Company's penetration into new business areas, the development plans of the company, the expected timing and results of such development and the expectation by management that there will be sufficient cash to meet the fiscal year's financial requirements. We can provide no assurance that such development will proceed as currently anticipated, that the expected timing or results of such development will be realized or that the company will be able to generate sufficient cash to meet its obligations. We are subject to various risks, including the uncertainties of product development, markets for our products and regulatory review, our need for additional capital to fund our operations, our reliance on collaborative partners, our history of losses, and other risks inherent in the biotechnology industry.
For more information, please contact: Mr. William P. Long (Chief Executive Officer) USA. Tel: 609-267-9118, Email: Investors@EpicoreBioNetworks.com
The Board of Directors of Epicore BioNetworks Inc. is pleased to announce a new director has joined the board, effective April 23, 2011. The Board welcomes Mr. Robert S. Poulton of Seattle, WA, USA.
Mr. Poulton is Senior Vice President for Global Quality for Dendreon Corporation of Seattle, WA. He has over twenty-five years of experience in production, quality assurance and regulatory compliance in the pharmaceuticals industry. He has held officer and board positions and worked in several world areas. Mr. Poulton holds an honors degree in applied chemistry from Brighton Polytechnic. The Board expects that his knowledge and experience, particularly in the area of production and quality will be of great benefit to Epicore as it embarks on a more aggressive infrastructure improvement program and completes its ISO-9001:2008 registration program.
The Board of Directors has approved issuance to Mr. Poulton of 200,000 options to buy Epicore common shares. Additionally, 100,000 options were issued to non-executive directors of the company. The grants follow Company board compensation policy. The options being issued have an exercise price of Cdn $0.12 per share and expire in five years. The 300,000 options granted is equivalent to 1.3% of Epicore's issued common stock. Under the terms of the Epicore Stock Option Plan, which was approved by shareholders at the Company's Annual General and Special Meetings of Shareholders, options may be issued from time to time in any amount up to a maximum of 4,704,246.
The Board of Directors also announces the resignation of Mr. Michael Perrault from the board effective April 12, 2011. Mr. Perrault faithfully served the board since October 2008. The Board of Directors thanks him for his service and wishes him the best in his future activities.
Epicore BioNetworks Inc. is a leading producer of environmental biotechnology and animal nutrition products. It manufactures in the USA and markets worldwide to a variety of industries to reduce environmental pollution and increase operational productivity.
Epicore BioNetworks Inc. is a public corporation with a registered office in Calgary, Alberta, Canada and with shares listed on the TSX Venture Exchange (symbol EBN). [Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.]
This press release contains forward-looking statements that involve significant risks and uncertainties. The actual results, performance or achievements of the company might differ materially from the results, performance or achievements of the company expressed or implied by such forward-looking statements. Such forward-looking statements include, without limitation, those regarding the future growth of the Company, expected improvements in the quality and reliability of manufacturing operations, acceleration of the Company's penetration into new business areas, the development plans of the company, the expected timing and results of such development and the expectation by management that there will be sufficient cash to meet the fiscal year's financial requirements. We can provide no assurance that such development will proceed as currently anticipated, that the expected timing or results of such development will be realized or that the company will be able to generate sufficient cash to meet its obligations. We are subject to various risks, including the uncertainties of product development, markets for our products and regulatory review, our need for additional capital to fund our operations, our reliance on collaborative partners, our history of losses, and other risks inherent in the biotechnology industry.
For more information, please contact: Mr. William P. Long (Chief Executive Officer) USA. Tel: 609-267-9118, Email: Investors@EpicoreBioNetworks.com
Please click on the links below to view the press release:
Stock Option Press Release December 2, 2011
Epicore's Aquaculture Business Development Director, Fernando Garcia, was one of eight speakers at the opening session of the Indonesian Aquaculture meeting, held October 4 to 6 in Jakarta. Fernando presented an overview of how the Brazilian industry coped with IMNV disease through changed culturing practices and the use of probiotics like Epicore's EPICIN-G2.
Click on the image to read the complete story behind
Epicore BioNetworks centrifugal sifting technology.
Epicore reaches out directly to shrimp farmers in the northwest province of Vietnam, holding a well attended seminar in Mong Cai city for about 35 farmers. This province has moved completely to vannamei and are stocking in high densities between 100 to 200/m2, using Epicore products and technology to protect against environmental conditions.
Epicore is pleased to announce successful commercial trials with the newest formulation of its flagship aquaculture probiotic: EPICIN®. With over 15 years commercial usage in over twenty-five countries EPICIN is one of most widely recognized aquaculture probiotics. Its record of delivering consistent quality and excellent performance in aquaculture hatcheries and ponds is unequaled. Epicore’s goal is to provide the best and the most cost-effective aquaculture products possible. In this spirit of continuous product improvement, research began three years ago to develop a simple to use formulation of EPICIN. This work produced EPICIN-PILLS, a ten-gram pill of 30 mm diameter and 11 mm thickness. The pill form can be added to aquaculture systems with no prior hydration. Its pre-measured form makes dosing systems as close to foolproof as possible.
Although originally conceived for aquaculture grow-out ponds, EPICIN-PILLS found its first use in Ecuador in shrimp hatcheries in 2008. Ease of use and consistent dosing were big appeals. Because of its high strength of probiotic microbes, the number of pills added to the system is low. Hatchery managers report the same effective control of water pollutants, like ammonia, and the same control of pathogen organisms as with regular EPICIN.
EPICIN-PILLS also is providing good performance in Ecuadorian shrimp raceways. Ing. Ac. Angel Norton, biologist in charge of raceways at the Barcelona Shrimp Farm Owned by the Mr. Ju Group and located in the Gulf of Guayaquil comments: “I use the EPICIN-PILLS aquaculture treatment with fantastic results. I use two tablets per day per 80-ton tank for 21 days before and after stocking with 45 PL per liter. The results with EPICIN-PILLS were amazing. The water was clear with no odor. The level of green colonies in was less than 200 cfu per ml versus control levels up to 600 cfu per ml. Survival in the treated tanks was 89% versus 65% for the controls. This product is very easy to use: just throw it into the tank and solve pollution problems.”
Ecuadorian usage has expanded to shrimp larvae transport. Ing. Ac. Johnnie Loayza, shrimp biologist of Escalante Island Shrimp Farm, owned by Isla Bonita Company and located in the Gulf of Guayaquil, shares his experience with the use of EPICIN-PILLS: “I use one tablet for every five tons of water used to transport larvae from a Peninsula of Santa Elena hatchery to our farm, which is 400 km. away (an eight hour journey). With the EPICIN-PILLS use we see a marked improvement in health and activity of post larvae, reduced stress and increased survival. These results are simply very cost effective for my company.”
A new program recently launched in Ecuador uses EPICIN-PILLS in a pond-side grow-up program designed to deliver a large number of probiotic cells at a very economical cost. The protocol has advantages over reported low cost grow-up inoculants in the high strength of the EPICIN-PILLS starting seed culture and its consistent quality. Also, EPICIN-PILLS does not have gram-negative contaminants as some cheaper products do. Epicore Ecuador S.A. has launched the new product and protocol with the advertising line, “Mr. Aquaculturist, put an end to your headache with the most practical and secure solution: EPICIN-PILLS.”
In Mexico, where the pill form was originally targeted, grow-out farms used EPICIN-PILLS for the first time in 2009. Farmers were pleased with the ease of use and reported good performance in their ponds.
Treatment of aquaculture grow-out ponds with specially formulated products based on carefully selected, natural bacteria provides a natural way to eliminate pollution and to create a beneficial microbial environment that inhibits the development of harmful organisms. Bacteria have a powerful capacity to utilize pollutants such as ammonia, nitrates and nitrites in their normal metabolism. Additionally, a thriving culture of the right natural bacteria provide a “probiotic” environment which suppresses the growth of harmful organisms. Through these two mechanisms, a healthier aquatic creature is raised that has greater vitality and immunity to disease.
Epicore hosts educational seminars on a regular basis.
Please contact Fernando Garcia
for exact times and locations.
Fernando.Garcia@EpicoreBioNetworks.com
(Scroll down for a listing of planned events.)
None planned at this time.